摘要
目的对比研究吸入糖皮质激素（ICS）联合茶碱与联合长效β2受体激动剂（LABA）治疗支气管哮喘（简称哮喘）患者的临床效果差异。方法选取我院呼吸内科收集的98例哮喘患者作为观察对象，根据患者就诊单双号顺序分为观察组和对照组各49例，观察组患者采用ICS＋LABA疗法，对照组给予ICS＋茶碱疗法，对比分析2组患者的临床治疗效果优劣。结果治疗后观察组和对照组患者的FEV1、FVC、肺活量（VC）值较治疗前显著的降低、最高呼气流量（PEF）值显著的提高（t值分别为2．149、2．681、3．098、2．705，P值均〈0．05），治疗后观察组的FEV1、FVC、VC、PEF测定值显著的优于对照组（t值分别为2．964、2．582、2．517、3．029，P值均〈0．05）。治疗后观察组嗜酸粒细胞[（3．06±1．15）％]显著的低于对照组[（4．16±1．20）％]（t=3．117，P〈0．05）。治疗后观察组ACT评分[（27．1±2．9）分]显著的高于对照组[（25．5±2．6）分]（t=2．038，P〈0．05）。治疗后观察组的临床效果分布显著的优于对照组（Z=-2．049，P〈0．05）。结论ICS＋LABA疗法较ICS＋茶碱疗法治疗中度哮喘持续性发作患者具有更加显著的临床效果。
Objective To compare the clinical effect of inhaled corticosteroid （ICS） and combined with theophylline and combined with long acting beta 2 agonists （LABA） in the treatment of bronchial asthma （asthma）. Methods Sleeted 98 cases of patients with asthma is selected as the observation object, according to patients with odd and even number sequence is divided into the observation group and the control group with 49 cases in each. Patients in the observation group were given the therapy ICS ＋ LABA. The control group was given ICS＋ theophylline therapy, the contrast analysis of two groups of patients with clinical curative effect of the pros and cons. Results After treatment,the observation group and the control group of patients FEV1, FVC, VC value than before treatment significantly reduced, PEF was significantly improved （ t = 2. 149,2. 681,3. 098,2. 705, P 〈0.05）, FEV1 post-treatment observation group,FVC, VC, PEF measured values significantly superior in the control group （t = 2. 964, 2. 582, 2. 517,3. 029, P 〈0.05）. After treatment,the observation group of eosinophils [（3.06±1.15）%] was significantly lower than the control group [（4.16 ±1.20）%] （ t =3. 117, P 〈0.05）. ACT scores after treatment in the observation group （27. 1±2. 9） points significantly higher than that of （25. 5±2.6） min （ t = 2. 038, P 〈0.05）. The clinical effect of the distribution of the observation group after treatment was significantly better than the control group （ Z =--2. 049, P 〈0.05）. Conclusions ICS＋LABA therapy is more significant in the treatment of patients with moderate asthma with ICS4-theophylline.
出处
《国际呼吸杂志》
2015年第23期1773-1776,共4页
International Journal of Respiration
